Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in epithelial ovarian cancer: State of the art

Table 2 Cytoreductive surgery + hyperthermic intraperitoneal chemotherapy in the treatment of advanced stage primary epithelial ovarian cancer: prospective phase 2 trials

Ref.	n	Disease stage	Setting of treatment	HIPEC drug used and dose	Temp. (°C)	Duration of treatment (min)	OS (mo)	PFS (mo)	Common grade 2-3 toxicities	Mortality rate
Di Giorgio et al[47]	47	3C-4 EOC	22 primary	Cisplatin 75 mg/m2	42-43	60	30.4 (mean)	27.4 (mean)	Pleural effusions (8.5%)	4% (PE)
			25 recurrent						Infectious (8.5%)
									GI (10.6%)
									Bleeding (6.4%)
Lim et al[48]	30	3-4 EOC	30 primary (14 of which underwent neoadjuvant treatment)	Cisplatin 75 mg/m2	41.5	90	NR	NR	Hematologic (86.7%)	No deaths
									GI (30%)
									Infectious (16.7%)
									Pulmonary (23.3%)
									CV (13.3%)
Ansaloni et al[49]	26	3-4 EOC	26 primary	Cisplatin 40 mg/L perfusate + doxorubicin 15 mg/L perfusate	42.5	90	Not reached	30 (median)	Hematologic (4%)	4% (sepsis)
							5-yr OS 60.7%	5-yr PFS 15.2%	GI (4%)
									Pulmonary (14.3%)
									Infectious (14.3%)

Ninety-three percent with complete response to primary treatment. Seven patients with progressive disease. HIPEC: Hyperthermic intraperitonealchemotherapy; Temp.: Temperature; OS: Overall survival; PFS: Progression free survival; EOC: Epithelialovarian cancer; GI: Gastrointestinal; PE: Pulmonary embolism; NR: Not reported; CV: Cardiovascular.